Get started

Financials · LEXX

Lexaria Bioscience Corp. (LEXX) financials

For the twelve months ended May 31, 2026, Lexaria Bioscience Corp. reported $194.0K of revenue and -$7.73M of net income.

Revenue, TTM
$194.0K
Revenue growth, YoY
-68.5%
Net income, TTM
-$7.73M
Net margin
-3985.6%
Free cash flow, TTM
-$7.47M
EPS, diluted, TTM
-$0.35
Cash
$3.50M
P/S
48.86
Market cap
$9.5M
Annual revenue$705.9K
FY2016FY2025
Annual net income-$11.90M
FY2016FY2025
Annual free cash flow-$10.48M
FY2016FY2025

LEXX revenue and earnings growth

LEXX revenueQ3 2026$0

Quarter YoY
-100.0%
QoQ
-100.0%
FY YoY
+52.0%
5Y CAGR
+17.5%

LEXX revenue was $0 in fiscal Q3 2026 (ended May 31, 2026), down 100.0% from a year earlier and down 100.0% from the prior quarter. For the full fiscal 2025 it was $705.9K, up 52.0% from fiscal 2024. Compound annual growth was +17.5% over 5 years. It rose in 6 of the last 9 fiscal years.

LEXX net incomeQ3 2026-$1.99M

LEXX net income was -$1.99M in fiscal Q3 2026 (ended May 31, 2026), compared with -$3.79M a year earlier. For the full fiscal 2025 it was -$11.90M, compared with -$5.80M in fiscal 2024.

LEXX EPSQ3 2026-$0.08

LEXX diluted EPS was -$0.08 in fiscal Q3 2026 (ended May 31, 2026), compared with -$0.21 a year earlier. For the full fiscal 2025 it was -$0.66.

LEXX free cash flowQ3 2026-$1.64M

LEXX free cash flow was -$1.64M in fiscal Q3 2026 (ended May 31, 2026), compared with -$3.58M a year earlier. For the full fiscal 2025 it was -$10.48M, compared with -$5.00M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Aug 31, 2025
FY2024
Aug 31, 2024
FY2023
Aug 31, 2023
FY2022
Aug 31, 2022
FY2021
Aug 31, 2021
FY2020
Aug 31, 2020
FY2019
Aug 31, 2019
FY2018
Aug 31, 2018
FY2017
Aug 31, 2017
FY2016
Aug 31, 2016
Revenue$705.9K$464.3K$226.2K$255.4K$722.7K$314.8K$222.6K$433.3K$63.6K$40.7K
Cost of revenue$2.7K$4.8K$31.5K$71.8K$175.3K$99.4K$22.9K$25.2K$29.8K$45.6K
Gross profit$703.2K$459.5K$194.7K$183.6K$547.4K$215.4K$199.7K$408.1K$33.9K-$4.9K
Research and development$8.24M$2.36M$3.67M$1.84M$1.26M$387.1K$555.7K$492.9K$54.2K$9.0K
Selling, general and admin$4.35M$3.85M$3.06M$4.96M$4.97M$3.98M$297.2K$217.7K$129.7K$133.7K
Operating income-$11.88M-$5.75M-$6.53M-$6.62M-$5.69M-----$1.28M
Interest expense--------$6.0K$2.3K
Pre-tax income-$11.91M-$5.81M-$6.71M-$7.38M-$4.17M-$3.99M-$4.16M-$6.61M-$1.93M-$1.27M
Income tax---$0$6.1K$2.3K$17.7K$0$0$0
Net income-$11.90M-$5.80M-$6.66M-$7.27M-$4.03M-$4.08M-$4.16M-$6.61M-$1.93M-$1.28M
EPS, basic-----$0.95-$1.47-$0.05-$0.09-$0.03-$0.03
EPS, diluted-$0.66-$0.47-$1.01--$0.95-$1.47-$0.05-$0.09-$0.03-$0.03
Diluted shares18.0M12.4M6.6M-4.4M2.8M77.8M71.0M58.8M43.8M

Balance sheet

Balance sheet
Line item
FY2025
Aug 31, 2025
FY2024
Aug 31, 2024
FY2023
Aug 31, 2023
FY2022
Aug 31, 2022
FY2021
Aug 31, 2021
FY2020
Aug 31, 2020
FY2019
Aug 31, 2019
FY2018
Aug 31, 2018
FY2017
Aug 31, 2017
FY2016
Aug 31, 2016
Cash and equivalents$1.80M$6.50M$1.35M$5.81M$10.92M$1.29M$1.29M$1.73M$2.53M$93.4K
Short-term investments$143.3K$55.8K$125.6K$347.3K$833.8K$19.3K$64.2K$10.2K$0-
Receivables$368.4K$154.5K$126.7K$201.8K$342.4K$313.9K$273.1K$265.8K$45.3K$131.1K
Inventory--$0$38.4K$29.6K$116.9K$127.4K$87.2K$67.2K$134.7K
Current assets$3.47M$7.90M$2.15M$6.98M$12.44M$1.93M$1.82M$2.28M$2.80M$510.2K
Total assets$4.18M$8.87M$3.08M$7.83M$13.27M$2.83M$2.68M$2.43M$2.86M$566.6K
Current liabilities$1.49M$1.10M$267.7K$194.0K$153.3K$225.9K$184.5K$43.6K$92.3K$433.9K
Total liabilities$1.57M$1.21M$403.9K$201.4K$203.3K$346.0K$184.5K$43.6K$92.3K$478.9K
Shareholders' equity$2.99M$7.66M$2.68M$7.63M$13.06M$2.48M$2.49M$2.39M$2.77M$87.8K

Cash flow

Cash flow
Line item
FY2025
Aug 31, 2025
FY2024
Aug 31, 2024
FY2023
Aug 31, 2023
FY2022
Aug 31, 2022
FY2021
Aug 31, 2021
FY2020
Aug 31, 2020
FY2019
Aug 31, 2019
FY2018
Aug 31, 2018
FY2017
Aug 31, 2017
FY2016
Aug 31, 2016
Operating cash flow-$10.45M-$4.96M-$5.88M-$4.88M-$3.99M-$2.62M-$3.01M-$2.52M-$1.55M-$660.9K
Capital expenditures$24.6K$43.0K$33.7K$49.2K-$0$646.2K-$0$3.1K
Free cash flow-$10.48M-$5.00M-$5.91M-$4.93M--$2.62M-$3.65M--$1.55M-$664.0K
Investing cash flow-$243.0K-$188.6K-$169.6K-$180.6K$193.9K-$26.8K-$769.2K-$155.4K-$9.7K-$20.1K
Financing cash flow$6.05M$10.32M$1.59M-$44.6K$13.42M$2.65M$3.33M$1.87M$4.00M$514.3K
Stock-based compensation$859.5K$492.2K$170.4K$752.6K$410.0K----$122.0K
Depreciation and amortization$51.2K$42.4K$145.4K$102.7K$111.7K-----

Key ratios

Key ratios
Line item
FY2025
Aug 31, 2025
FY2024
Aug 31, 2024
FY2023
Aug 31, 2023
FY2022
Aug 31, 2022
FY2021
Aug 31, 2021
FY2020
Aug 31, 2020
FY2019
Aug 31, 2019
FY2018
Aug 31, 2018
FY2017
Aug 31, 2017
FY2016
Aug 31, 2016
Revenue growth, YoY52.0%105.2%-11.4%-64.7%129.6%41.4%-48.6%580.9%56.3%-
Gross margin99.6%99.0%86.1%71.9%75.7%68.4%89.7%94.2%53.3%-12.0%
Operating margin-1683.0%-1239.2%-2888.5%-2591.7%-786.8%-----3136.8%
Net margin-1686.0%-1248.2%-2946.4%-2846.3%-557.2%-1297.6%-1868.0%-1525.4%-3031.9%-3136.8%
Free cash flow margin-1483.9%-1077.4%-2614.8%-1929.8%--831.9%-1640.4%--2429.2%-1630.6%
Return on equity-398.1%-75.7%-248.7%-95.2%-30.8%-164.6%-167.0%-276.7%-69.7%-1455.4%
Return on assets-285.1%-65.4%-216.1%-92.8%-30.4%-144.4%-155.4%-271.8%-67.5%-225.4%
Current ratio2.327.188.0335.9681.188.539.8652.3430.271.18

Source: XBRL data Lexaria Bioscience Corp. files with the SEC, latest filing dated Jul 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

LEXX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
LEXX$194.0K-68.5%-$7.73M-3985.6%$9.5M
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

LEXX FAQ

9 questions
  • What is LEXX revenue?
    Lexaria Bioscience Corp. (LEXX) reported $194.0K of revenue for the twelve months ended May 31, 2026. That is down 68.5% from the year before. Revenue for fiscal 2025 was $705.9K.
  • Is LEXX profitable?
    No. Lexaria Bioscience Corp. reported a net loss of $7.73M for the twelve months ended May 31, 2026.
  • How much cash and debt does LEXX have?
    Lexaria Bioscience Corp. reported $3.50M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is LEXX revenue growing?
    Lexaria Bioscience Corp.'s revenue changed +52.0% in fiscal 2025, to $705.9K. Its compound annual growth rate was +17.5% over 5 years.
  • What is LEXX gross margin?
    Lexaria Bioscience Corp.'s gross profit was $194.0K on $194.0K of revenue for the twelve months ended May 31, 2026, a gross margin of 100.0%.
  • What is LEXX free cash flow?
    Lexaria Bioscience Corp. generated -$7.47M of free cash flow for the twelve months ended May 31, 2026, which is operating cash flow of -$7.43M less capital expenditures.
  • What is LEXX earnings per share?
    Diluted earnings per share were -$0.35 for the twelve months ended May 31, 2026, from SEC filings, restated for any stock split those filings show.
  • When did LEXX last report financial results?
    The latest statements here come from Lexaria Bioscience Corp.'s 10-Q filed on Jul 13, 2026, covering the period ended May 31, 2026.
  • Where does this LEXX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Lexaria Bioscience Corp. files with the SEC. It is provided for information only and is not investment advice.